groups was small compared with other costs in the analysis, and the association
between costs, intervention group and time period were unclear, the differences were
not included in the base case economic evaluation findings.
The costs of training staff and ongoing activity under DCM and PCC are shown in
Table 3. Since the pharmaceutical cost data were not significantly different between
intervention groups, they are not listed as a cost difference (this issue will be
investigated in the sensitivity analysis). Costs associated with critical incidents, or
general doctor time were not included as there was uncertainty regarding the
comparability of data collection methods in these areas.